PD-1/PD-L1与心肌炎的关系:一项孟德尔随机化研究
Association between PD-1/PD-L1 and Myocarditis: A Mendelian Randomization Study
DOI: 10.12677/acm.2024.1482389, PDF,    科研立项经费支持
作者: 曾亮嘉:广州医科大学南山学院,广东 广州;周若筠:广州医科大学第三临床学院,广东 广州;杨文婷, 冯曼婷, 梁英岚*:广州医科大学第二临床学院,广东 广州
关键词: 孟德尔随机化心肌炎PD-1PD-L1因果关系Mendelian Randomization Myocarditis PD-1 PD-L1 Causal Relationship
摘要: 目的:利用两样本,多变量及双向孟德尔随机化(MR)研究设计,探究程序细胞死亡蛋白1 (programmeddeath-1, PD-1)及其配体(PD-1 ligand, PD-L1)与心肌炎风险的因果关联。方法:从公开全基因组关联研究(GWAS)中提取PD-1/PD-L1与心肌炎的工具变量。采用逆方差加权法(IVW)作为主要的MR分析方法,辅以加权中位数(WM)、Robust adjusted profile score (RAPS)、MR-Egger、孟德尔随机化多效性残差和异常值(MR-PRESSO)、Cochran’s Q检验、留一法、水平多效性分析作为敏感性分析。结果:两样本MR的IVW结果提示,PD-L1与心肌炎具有负向因果关联[比值比(OR),0.619;95%置信区间(CI),0.434~0.884;P,0.008],敏感性分析结果表明因果关系稳健。在多变量MR中,PD-L1与心肌炎的负向因果关系依然存在(OR, 0.658; 95% CI, 0.47~0.92, P, 0.015)。PD-1与心肌炎,心肌炎与PD-1/PD-L1的因果关联没有统计学意义。结论:该研究为PD-L1与心肌炎之间的负向因果关联提供了新的证据,而PD-1与心肌炎,心肌炎与PD-1/PD-L1没有直接因果关系。
Abstract: Objective: To investigate the causal association between programmed death-1 (PD-1) and its ligand (PD-1 ligand, PD-L1) and the risk of myocarditis using a two-sample, multivariate and bidirectional Mendelian randomization (MR) study design. Methods: Instrumental variables for PD-1/PD-L1 and myocarditis were extracted from public genome-wide association studies (GWAS). Inverse variance weighting (IVW) was used as the main MR analysis method, supplemented by weighted median (WM), Robusta adjusted profile score (RAPS), MR-Egger, Mendelian randomization pleiotropic residuals and outliers (MR-PRESSO), Cochran’s Q test, leave-one-out method, and horizontal pleiotropy analysis as sensitivity analyses. Results: The IVW results of the two-sample MR suggested that PD-L1 had a negative causal association with myocarditis [odds ratio (OR), 0.619; 95% confidence interval (CI), 0.434~0.884; P, 0.008], and the sensitivity analysis results showed that the causal relationship was robust. In multivariate MR, the negative causal relationship between PD-L1 and myocarditis still existed (OR, 0.658; 95% CI, 0.47-0.92; P, 0.015). The causal association between PD-1 and myocarditis, and between myocarditis and PD-1/PD-L1 was not statistically significant. Conclusion: This study provides new evidence for the negative causal association between PD-L1 and myocarditis, while there is no direct causal relationship between PD-1 and myocarditis, and between myocarditis and PD-1/PD-L1.
文章引用:曾亮嘉, 周若筠, 杨文婷, 冯曼婷, 梁英岚. PD-1/PD-L1与心肌炎的关系:一项孟德尔随机化研究[J]. 临床医学进展, 2024, 14(8): 1543-1558. https://doi.org/10.12677/acm.2024.1482389

参考文献

[1] 刘方圆, 高艳, 王文先, 史荣超, 李莎, 王锡明. 基于心脏磁共振晚期钆增强的心肌信号强度异质性对心肌炎患者预后价值的研究[J]. 磁共振成像, 2024, 15(3): 68-73.
[2] 师维, 崔旋旋, 周伍明, 华天凤, 杨旻. 1990-2019年中国心肌炎疾病负担水平及其变化分析[J]. 医学新知, 2023, 33(5): 325-333.
[3] Lucas, J.A., Menke, J., Rabacal, W.A., Schoen, F.J., Sharpe, A.H. and Kelley, V.R. (2008) Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice. The Journal of Immunology, 181, 2513-2521. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, J., Okazaki, I., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., et al. (2010) PD-1 Deficiency Results in the Development of Fatal Myocarditis in MRL Mice. International Immunology, 22, 443-452. [Google Scholar] [CrossRef] [PubMed]
[5] Tarrio, M.L., Grabie, N., Bu, D., Sharpe, A.H. and Lichtman, A.H. (2012) PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis. The Journal of Immunology, 188, 4876-4884. [Google Scholar] [CrossRef] [PubMed]
[6] Tsuruoka, K., Wakabayashi, S., Morihara, H., Matsunaga, N., Fujisaka, Y., Goto, I., et al. (2020) Exacerbation of Autoimmune Myocarditis by an Immune Checkpoint Inhibitor Is Dependent on Its Time of Administration in Mice. International Journal of Cardiology, 313, 67-75. [Google Scholar] [CrossRef] [PubMed]
[7] Dong, H., Qi, Y., Kong, X., Wang, Z., Fang, Y. and Wang, J. (2022) PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Frontiers in Pharmacology, 13, Article 835510. [Google Scholar] [CrossRef] [PubMed]
[8] Moslehi, J., Lichtman, A.H., Sharpe, A.H., Galluzzi, L. and Kitsis, R.N. (2021) Immune Checkpoint Inhibitor—Associated Myocarditis: Manifestations and Mechanisms. Journal of Clinical Investigation, 131, e145186. [Google Scholar] [CrossRef] [PubMed]
[9] 汪潇潇, 陈万一. PD-1/PD-L1抑制剂相关心肌炎不良反应——基于三大报告系统的真实世界研究[J]. 中国新药杂志, 2019, 28(11): 1404-1408.
[10] Levin, M.G. and Burgess, S. (2024) Mendelian Randomization as a Tool for Cardiovascular Research: A Review. JAMA Cardiology, 9, 79-89. [Google Scholar] [CrossRef] [PubMed]
[11] 于天琦, 徐文涛, 苏雅娜, 李静. 孟德尔随机化研究基本原理、方法和局限性[J]. 中国循证医学杂志, 2021, 21(10): 1227-1234.
[12] 夏晓琳, 刘晔, 徐晓冰, 孟俊彤, 王艳. 甲状腺功能减退症与冠心病因果关系的孟德尔随机化研究[J]. 现代预防医学, 2024, 51(3): 412-416.
[13] 杨梦霞, 赵春铭, 陈腾飞, 徐霄龙, 刘清泉. 脓毒症与心律失常因果关联的两样本孟德尔随机化研究[J]. 中国急救医学, 2024, 44(2): 142-147.
[14] Davies, N.M., Holmes, M.V. and Davey Smith, G. (2018) Reading Mendelian Randomisation Studies: A Guide, Glossary, and Checklist for Clinicians. BMJ, 362, k601. [Google Scholar] [CrossRef] [PubMed]
[15] 杜冬杰, 陈健, 王诗悦, 等. 血残粒胆固醇水平与冠心病和心肌梗死风险的两样本孟德尔随机化研究[J]. 中国动脉硬化杂志, 2023, 31(6): 510-516.
[16] Larsson, S.C., Butterworth, A.S. and Burgess, S. (2023) Mendelian Randomization for Cardiovascular Diseases: Principles and Applications. European Heart Journal, 44, 4913-4924. [Google Scholar] [CrossRef] [PubMed]
[17] Sun, B.B., Maranville, J.C., Peters, J.E., Stacey, D., Staley, J.R., Blackshaw, J., et al. (2018) Genomic Atlas of the Human Plasma Proteome. Nature, 558, 73-79. [Google Scholar] [CrossRef] [PubMed]
[18] Kurki, M.I., Karjalainen, J., Palta, P., Sipilä, T.P., Kristiansson, K., Donner, K.M., et al. (2023) Finngen Provides Genetic Insights from a Well-Phenotyped Isolated Population. Nature, 613, 508-518. [Google Scholar] [CrossRef] [PubMed]
[19] Burgess, S., Scott, R.A., Timpson, N.J., Davey Smith, G. and Thompson, S.G. (2015) Using Published Data in Mendelian Randomization: A Blueprint for Efficient Identification of Causal Risk Factors. European Journal of Epidemiology, 30, 543-552. [Google Scholar] [CrossRef] [PubMed]
[20] Verbanck, M., Chen, C., Neale, B. and Do, R. (2018) Detection of Widespread Horizontal Pleiotropy in Causal Relationships Inferred from Mendelian Randomization between Complex Traits and Diseases. Nature Genetics, 50, 693-698. [Google Scholar] [CrossRef] [PubMed]
[21] Zhao, Q., Wang, J., Hemani, G., Bowden, J. and Small, D.S. (2020) Statistical Inference in Two-Sample Summary-Data Mendelian Randomization Using Robust Adjusted Profile Score. The Annals of Statistics, 48, 1742-1769. [Google Scholar] [CrossRef
[22] Bowden, J., Davey Smith, G., Haycock, P.C. and Burgess, S. (2016) Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology, 40, 304-314. [Google Scholar] [CrossRef] [PubMed]
[23] Sanderson, E., Davey Smith, G., Windmeijer, F. and Bowden, J. (2018) An Examination of Multivariable Mendelian Randomization in the Single-Sample and Two-Sample Summary Data Settings. International Journal of Epidemiology, 48, 713-727. [Google Scholar] [CrossRef] [PubMed]
[24] Jo, W., Won, T., Daoud, A. and Čiháková, D. (2024) Immune Checkpoint Inhibitors Associated Cardiovascular Immune-Related Adverse Events. Frontiers in Immunology, 15, Article 1340373. [Google Scholar] [CrossRef] [PubMed]
[25] Salem, J., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., et al. (2018) Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study. The Lancet Oncology, 19, 1579-1589. [Google Scholar] [CrossRef] [PubMed]
[26] Moslehi, J.J., Salem, J., Sosman, J.A., Lebrun-Vignes, B. and Johnson, D.B. (2018) Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis. The Lancet, 391, 933. [Google Scholar] [CrossRef] [PubMed]
[27] Zhang, C., Wei, F., Ma, W. and Zhang, J. (2024) Immune-related Cardiovascular Toxicities of PD-1/PD-L1 Inhibitors in Solid Tumors: An Updated Systematic Review and Meta-Analysis. Frontiers in Immunology, 15, Article 1255825. [Google Scholar] [CrossRef] [PubMed]
[28] Sanderson, E., Glymour, M.M., Holmes, M.V., Kang, H., Morrison, J., Munafò, M.R., et al. (2022) Mendelian randomization. Nature Reviews Methods Primers, 2, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[29] Baik, A.H., Oluwole, O.O., Johnson, D.B., Shah, N., Salem, J., Tsai, K.K., et al. (2021) Mechanisms of Cardiovascular Toxicities Associated with Immunotherapies. Circulation Research, 128, 1780-1801. [Google Scholar] [CrossRef] [PubMed]
[30] Rubio-Infante, N., Ramírez-Flores, Y.A., Castillo, E.C., Lozano, O., García-Rivas, G. and Torre-Amione, G. (2021) Cardiotoxicity Associated with Immune Checkpoint Inhibitor Therapy: A Meta-Analysis. European Journal of Heart Failure, 23, 1739-1747.
https://pubmed.ncbi.nlm.nih.gov/34196077/
[31] Xia, W., Zou, C., Chen, H., Xie, C. and Hou, M. (2020) Immune Checkpoint Inhibitor Induces Cardiac Injury through Polarizing Macrophages via Modulating microRNA-34a/Kruppel-Like Factor 4 Signaling. Cell Death & Disease, 11, Article No. 575. [Google Scholar] [CrossRef] [PubMed]
[32] Wei, S.C., Meijers, W.C., Axelrod, M.L., Anang, N.A.S., Screever, E.M., Wescott, E.C., et al. (2021) A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discovery, 11, 614-625. [Google Scholar] [CrossRef] [PubMed]
[33] Yamaguchi, S., Morimoto, R., Okumura, T., Yamashita, Y., Haga, T., Kuwayama, T., et al. (2018) Late-Onset Fulminant Myocarditis with Immune Checkpoint Inhibitor Nivolumab. Canadian Journal of Cardiology, 34, 812.e1-812.e3. [Google Scholar] [CrossRef] [PubMed]
[34] Juchem, K.W., Sacirbegovic, F., Zhang, C., Sharpe, A.H., Russell, K., McNiff, J.M., et al. (2018) PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. The Journal of Immunology, 200, 834-846. [Google Scholar] [CrossRef] [PubMed]
[35] Bracamonte-Baran, W., Gilotra, N.A., Won, T., Rodriguez, K.M., Talor, M.V., Oh, B.C., et al. (2021) Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8+ T-Cell Infiltration after Heart Transplantation. Circulation: Heart Failure, 14, e007982. [Google Scholar] [CrossRef] [PubMed]
[36] Bishawi, M., Bowles, D., Pla, M.M., Oakes, F., Chiang, Y., Schroder, J., et al. (2021) PD-1 and PD-L1 Expression in Cardiac Transplantation. Cardiovascular Pathology, 54, Article ID: 107331. [Google Scholar] [CrossRef] [PubMed]
[37] Mahmood, S.S., Fradley, M.G., Cohen, J.V., Nohria, A., Reynolds, K.L., Heinzerling, L.M., et al. (2018) Myocarditis in Patients Treated with Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 71, 1755-1764. [Google Scholar] [CrossRef] [PubMed]
[38] Pillai, R.N., Behera, M., Owonikoko, T.K., Kamphorst, A.O., Pakkala, S., Belani, C.P., et al. (2017) Comparison of the Toxicity Profile of PD‐1 versus PD‐L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature. Cancer, 124, 271-277. [Google Scholar] [CrossRef] [PubMed]
[39] Li, W. and Wang, W. (2023) Unraveling the Genetic Associations between PD-1/PD-L1 and 13 Circulating Biomarkers Linked to Physiological and Pathological Processes. Clinical and Translational Oncology, 26, 1157-1169. [Google Scholar] [CrossRef] [PubMed]
[40] Ference, B.A., Majeed, F., Penumetcha, R., Flack, J.M. and Brook, R.D. (2015) Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both: A 2 × 2 Factorial Mendelian Randomization Study. Journal of the American College of Cardiology, 65, 1552-1561. [Google Scholar] [CrossRef] [PubMed]
[41] Zou, X., Wang, S., Wang, L., Xiao, L., Yao, T., Zeng, Y., et al. (2021) Childhood Obesity and Risk of Stroke: A Mendelian Randomisation Analysis. Frontiers in Genetics, 12, Article 727475. [Google Scholar] [CrossRef] [PubMed]